Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 14, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 735,000 ordinary shares of 25 pence each.
- Purchase Price: 1,366.8248 pence per share.
- Treasury Holdings: 112,818,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,832,643,289 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed this purchase on September 14, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 735,000 shares by the price of 1,366.8248 pence.
- Confirm the updated total share capital structure (5,832,643,289 issued shares plus 112,818,000 treasury shares).
- Review the authorization limits from the May 25, 2005 Annual General Meeting to determine remaining buyback capacity.